Here's some more good news. Pfizer/BioNTech's phase 3 trial has concluded after reaching its primary efficacy endpoints, and saw a boost from 90% to 95% efficacy. And this press release at least has more information than the last one. What does it say?https://t.co/ssgUBvWNiG

— Dr. Angela Rasmussen (@angie_rasmussen) November 18, 2020